Successful Salvage with Inotuzumab Ozogamicin in Relapsed/Refractory Lymphoid Blast Crisis of Chronic Myeloid Leukemia after Failure of Multiple Lines of Therapy Including Blinatumomab

Conclusion: Patients with relapsed/refractory lymphoid blast phase CML should receive directed salvage therapies. This case report demonstrates that failure of one line of directed therapy does not predict for future failures.DisclosuresNo relevant conflicts of interest to declare.

http://www.bloodjournal.org/cgi/content/short/132/Suppl_1/5452?rss=1

Source: Blood - November 21, 2018 Category: Hematology Authors: Mansurov, A., Byrne, M., Krishnan, K. Tags: 632. Chronic Myeloid Leukemia: Therapy Source Type: research